Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Korro Bio, Inc.

Get SEC filing alerts via email and in your feed for Korro Bio, Inc.

KRRO

Korro Bio, Inc.

About Korro Bio, Inc.

Korro Bio is a clinical-stage biopharmaceutical company developing RNA editing therapies to treat rare and prevalent diseases. Using its proprietary OPERA platform, it designs oligonucleotides to recruit endogenous ADAR enzymes for precise, transient RNA modifications. Its focus includes gene repair, protein modulation, and addressing undruggable targets, with a pipeline targeting conditions like alpha-1 antitrypsin deficiency, leveraging established delivery methods and aiming for disease-modifying, safe, and scalable genetic medicines.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Korro Bio, Inc.

1
1
Korro Bio, Inc. Korro Bio Reports Q1 2026 Financial Results with $19.6M Net Loss and Improved Cash Position

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Korro Bio, Inc. Korro Bio Reports $117.3 Million Net Loss and Strategic Updates in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Korro Bio, Inc. Korro Bio Reports $1.1 Million Collaboration Revenue in Q3 2025, Net Loss of $18.1 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Korro Bio, Inc. Korro Bio Reports $1.5 Million Collaboration Revenue and Increased Operating Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Korro Bio, Inc. Korro Bio Reports $23.4 Million Net Loss in Q1 2025, Highlights Collaboration Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Korro Bio, Inc. Korro Bio Reports $83.6 Million Net Loss and Increased Collaboration Revenue in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Korro Bio, Inc. Korro Bio Reports Significant Changes in Financial Position and Performance, Anticipates Continued Operating Losses

Via official filing (AI summary) | over 1 year ago | 0 comments